Skip to main content


Showing posts with the label HSQ_PDD


  Functioning The GAS and GAF have been ‘a standard’ to assess global functioning. The social and occupational functioning scale: SOFAS,16 which is a functional derivative of the GAF, has been described only sporadically. They are indeed quite simple and user-friendly but might be too simple to capture functional status. Ongoing efforts in this respect include the personal and social performance scale: PSP29 which modelled the SOFAS, and the functional assessment for comprehensive treatment in schizophrenia: FACT-Sz30 which is similar to the GAF but more detailed and more widely differentiates patients.   It has however been infrequent that functional scales, in contrast to symptomatic rating scales, have constituted the primary outcome measure in studies for schizophrenia,31-34 although global functioning appears to serve as a heuristic outcome that may represent ‘the net effect of everything’ in patients. Some studies on child and adolescent schizophrenia used the Children’s version

Scales for Adverse Effects

Adverse Effects This domain mainly consists of two parts—EPS and non-EPS adverse effects. As for the former, the combination of the AIMS (tardive involuntary movement), BARS (akathisia) and SAS (parkinsonism) appear to have been ‘a standard’. The ESRS has been much less commonly used although comprehensive, well presumably due to a lengthy process to complete. This topic has recently been reviewed in detail elsewhere.24 A major challenge here is how to interpret different scales with different item numbers as ‘an overall EPS burden’ within the subject in question. The drug-induced extrapyramidal symptoms scale: DIEPSS25 (nine items) might represent a useful alternative.   Non-motor adverse effects, including anticholinergic, metabolic, autonomic and sexual problems, have been usually described without the usage of the scales and sometimes reported in the table, for which standardization is warranted.26 Evaluations that depend on the spontaneous reports may result in underestimation. Al


Symptoms The PANSS has been ‘the standard’ scale and is frequently adopted as the primary outcome measure in clinical studies for schizophrenia. It is reasonable to assume the more number of items (and the wider the potential score distribution) in a scale, the more likely one would be able to detect a difference but at the cost of time. In order to discern any difference, it might be better to rate as many scales as possible (e.g., all of the PANSS, BPRS, SAPS, and SANS), which nonetheless would be unrealistically time-consuming and in fact has been a case for none of the 150 studies investigated herein.   Redundancy within/across the scales is also of concern. For instance, factor analyses of the PANSS have identified several components19 and as such, rating these extracted factors instead of all 30 items might even be sufficient. In line with this view, efforts are ongoing to make simpler rating scales. For instance, The Clinical Global Impression-Schizophrenia scale: CGI-SCH20 is a


Discussion It was found that clinical trials in schizophrenia are likely to utilize the PANSS for psychopathology as well as the set of AIMS, BARS and SAS for EPS assessment. Overall frequency in the assessment scales for schizophrenia in an effort to evaluate multiple domains within the illness appeared to be similar across years, except for more recent attention on cognition, functioning and subjective perspectives. The PANSS together with the set of AIMS, BARS and SAS may be regarded as ‘the standard’ in clinical trials for schizophrenia. This ‘standard’ set of assessment scales is expected to take about 60 minutes (30–40/5–10/10/10 minutes for the PANSS/AIMS/BARS/SAS, respectively).2 Such a time requirement obviously represents an obstacle for real-world practice.   Studies have utilized different scales for their different interests and we can not be entirely certain about which scales are adequate in a specific study. It is important to acknowledge that all assessment scales do h


Others I n some of the studies, assessments were extended to premorbid adjustment, disability, comorbid substance use, prognostic evaluation, caregivers’ perspectives and aggression and so forth. However, none of the scales has been utilized for ≥10% of the studies in any of the respective years.


  Cognition While some of the cognitive assessments were performed in only 11% in the years 1999 and 2004, they were rated in 30% of the studies in 2009. And the assessments used showed much more variety in 2009, expanding from classical paper-pencil tests to computerized facial emotion recognition tests to multiple tests that are expressed in the context of a composite cognitive score.


Functioning The global assessment of functioning: GAF16 and its precedent global assessment scale: GAS17 has been the most frequently utilized scale. They simply rate the global status with a score of 0–100. Performance-based functional scales have been very rarely utilized.

Non-Motor Adverse Effects

Non-Motor Adverse Effects The Udvalg for Kliniske Undersogelser: UKU side effect rating scale15 (48 items plus interference and action items, eight of which evaluate neurologic adverse effects) has been the only scale that was utilized in 13% of the studies in 2004. In 1999, merely one of the 35 studies evaluated non-motor adverse effects with the rating scale (UKU). On the other hand, the frequency of treatment-emergent (motor and non-motor) adverse effects has been occasionally described in tables (spontaneously reported or observed but without the usage of the formal scales).

Extrapyramidal Symptoms

Extrapyramidal Symptoms It has been typical to assess parkinsonism with the Simpson–Angus scale: SAS11 (10 items), tardive movement disorders with the abnormal involuntary movement scale: AIMS12 (10 items plus two dental status items), akathisia with the Barnes akathisia rating scale: BARS13 (four items). These three scales were frequently rated altogether. In fact, if any one of these scales was assessed, both of the rest were also evaluated in 40% of the cases overall (and as high as 74% in 2009). The extrapyramidal symptom rating scale: ESRS14 (41 items plus 4 CGIs’ for akathisia, dyskinesia, dystonia and parkinsonism) has been used much less frequently. Copyright Notice Adapted from Wikipedia. Text is available under the  Creative Commons Attribution-ShareAlike License 3.0 ; additional terms may apply.

Classical Psychopathology (Positive and Negative Symptoms)

Classical Psychopathology (Positive and Negative Symptoms) As expected, almost all of the studies reported on this aspect with a usage of the rating scales. The PANSS (30-item—7 for positive, 7 for negative and 16 for general psychopathology subscales) has been by far the most frequently utilized scale for this purpose. It was followed by the BPRS (typically 18-item version), which outnumbered the PANSS in 1999, and was sometimes extracted from the PANSS (as 18-item version).   The next common scale was the scale for the assessment of negative symptoms: SANS7 (20 symptom items plus five global items) and the scale for the assessment of positive symptoms: SAPS8 (30 symptom items plus four global items). They were rated altogether at times (9 of 150 studies). Sometimes, the SANS was assessed together with the PANSS (8 of 150 studies).

Affective/Anxiety Symptoms

Affective/Anxiety Symptoms Although the frequency in usage was rather low, the Hamilton rating scale for depression: HRSD9 (typically 17 items), and more recently the Calgary depression rating scale for schizophrenia: CDSS10 (nine items) have been the most frequently recorded scale. In contrast, subjective scales for depression have very rarely been utilized. Rating scales for anxiety symptoms, both objective and subjective, have been barely used.

Global Evaluation

Global Evaluation The clinical global impression: CGI6 has been the sole scale used as a global measure. It simply evaluates the severity of illness (normal:1 to moderate:4 to most ill:7) as well as change (very much improvement: 1 to no change:4 to very much worsening:7) with a score of 1–7. No other global evaluation scales for severity and change have been utilized.

Nisonger Child Behavior Rating Form (NCBRF)

Nisonger Child Behavior Rating Form (NCBRF) The NCBRF [62] has six problem behaviour subscales: Conduct Problem, Insecure/Anxious, Hyperactive, Self-Injury/Stereotypic, Self-isolated/Ritualistic, and Overly Sensitive. Internal consistency of the problem behaviour scales was reported as good with Cronbach’s alpha >0.70 for all subscales in both parent and teacher versions [68]. Test-retest reliability for the parent version was reported to be strong (ICC for total problem behaviour >0.80) but the teacher version fell short of the COSMIN criterion (ICC for total problem behaviour = 0.68); however, over a one year time interval, some change might well be expected. The agreement was low between parents and teachers on common items from the parent and teacher versions of the scale, indicating that inter-rater reliability was poor [69]. Structural validity was also shown to be poor for problem behaviour with a 5-factor solution accounting for 47.5% of the variance [68]. Finally, Lecava